Court rejects Celexa patent listing
Executive Summary
FDA's "ministerial" role in declining to list certain patents in the "Orange Book" affirmed by a D.C. federal judge Aug. 13. Court rules FDA did not err in refusing Alphapharm's request to list a patent for Forest's antidepressant Celexa and accept its ANDA with a Paragraph IV certification. No patents for Celexa are listed; consequently, no ANDA filers will receive 180-day exclusivity for generic citalopram...